CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 269 enrolled
Drug / intervention
TMP-SMX +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03637400
NCT03637400Phase 2Completed
CompareCT.gov

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Treatment of Uncomplicated Skin and Soft Tissue Infections

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Aug 20, 2018·Updated Dec 4, 2025

In Brief

A Phase 2 clinical trial evaluating TMP-SMX and DOXY for Methicillin-resistant Staphylococcus Aureus and Skin Infection. Completed, enrolled 269 participants across 3 sites.

Detailed Summary

The purpose of this study is to compare how well two different antibiotics, doxycycline (DOXY) and trimethoprim/sulfamethoxazole (TMP/SMX), work at curing uncomplicated skin and soft tissue infection (uSSTI) such as 1.Boils (pus in the skin, also known as abscesses and furuncles) or 2. Infections that appear only on the skin surface (called cellulitis and erysipelas) that have pus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethicillin-resistant Staphylococcus Aureus, Skin Infection
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), Washington University School of Medicine, University of California, Los Angeles

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 20, 2018
Enrollment StartNov 26, 2018
Primary CompletionFeb 12, 2024
Study CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.9 years ago

Interventions

TMP-SMXdrug

TMP-SMX will be administered over a period of 7 days.

DOXYdrug

DOXY will be administered over a period of 7 days.